These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1109 related articles for article (PubMed ID: 15337695)

  • 1. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
    Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
    Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of nesiritide on renal function in patients admitted for decompensated heart failure.
    Arora S; Clarke K; Srinivasan V; Gradman A
    QJM; 2007 Nov; 100(11):699-706. PubMed ID: 17971392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
    Kurien S; Warfield KT; Wood CM; Miller WL
    Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide.
    Miller WL; Kurien S; Warfield KT; Wood CM; Jaffe AS
    Int J Cardiol; 2008 May; 126(2):234-9. PubMed ID: 17482692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
    Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
    J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of nesiritide in pediatric heart failure.
    Jefferies JL; Price JF; Denfield SW; Chang AC; Dreyer WJ; McMahon CJ; Grenier MA; Clunie SK; Thomas A; Moffett BS; Wann TS; Smith EO; Towbin JA
    J Card Fail; 2007 Sep; 13(7):541-8. PubMed ID: 17826644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients.
    Chow SL; Peng JT; Okamoto MP; Heywood JT
    Ann Pharmacother; 2007 Apr; 41(4):556-61. PubMed ID: 17389662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
    Aronson D; Burger AJ
    Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study.
    Chen HH; Sundt TM; Cook DJ; Heublein DM; Burnett JC
    Circulation; 2007 Sep; 116(11 Suppl):I134-8. PubMed ID: 17846293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery.
    Ejaz AA; Martin TD; Johnson RJ; Winterstein AG; Klodell CT; Hess PJ; Ali AK; Whidden EM; Staples NL; Alexander JA; House-Fancher MA; Beaver TM
    J Thorac Cardiovasc Surg; 2009 Oct; 138(4):959-64. PubMed ID: 19660420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF).
    van Deursen VM; Hernandez AF; Stebbins A; Hasselblad V; Ezekowitz JA; Califf RM; Gottlieb SS; O'Connor CM; Starling RC; Tang WH; McMurray JJ; Dickstein K; Voors AA
    Circulation; 2014 Sep; 130(12):958-65. PubMed ID: 25074507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial.
    Yancy CW; Krum H; Massie BM; Silver MA; Stevenson LW; Cheng M; Kim SS; Evans R;
    Circ Heart Fail; 2008 May; 1(1):9-16. PubMed ID: 19808265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.
    Sackner-Bernstein JD; Skopicki HA; Aaronson KD
    Circulation; 2005 Mar; 111(12):1487-91. PubMed ID: 15781736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment.
    Miller AH; Nazeer S; Pepe P; Estes B; Gorman A; Yancy CW
    Ann Emerg Med; 2008 May; 51(5):571-8. PubMed ID: 18304693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nesiritide in patients with acute decompensated heart failure.
    O'Connor CM; Starling RC; Hernandez AF; Armstrong PW; Dickstein K; Hasselblad V; Heizer GM; Komajda M; Massie BM; McMurray JJ; Nieminen MS; Reist CJ; Rouleau JL; Swedberg K; Adams KF; Anker SD; Atar D; Battler A; Botero R; Bohidar NR; Butler J; Clausell N; Corbalán R; Costanzo MR; Dahlstrom U; Deckelbaum LI; Diaz R; Dunlap ME; Ezekowitz JA; Feldman D; Felker GM; Fonarow GC; Gennevois D; Gottlieb SS; Hill JA; Hollander JE; Howlett JG; Hudson MP; Kociol RD; Krum H; Laucevicius A; Levy WC; Méndez GF; Metra M; Mittal S; Oh BH; Pereira NL; Ponikowski P; Tang WH; Tanomsup S; Teerlink JR; Triposkiadis F; Troughton RW; Voors AA; Whellan DJ; Zannad F; Califf RM
    N Engl J Med; 2011 Jul; 365(1):32-43. PubMed ID: 21732835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure).
    Gottlieb SS; Stebbins A; Voors AA; Hasselblad V; Ezekowitz JA; Califf RM; O'Connor CM; Starling RC; Hernandez AF
    J Am Coll Cardiol; 2013 Sep; 62(13):1177-83. PubMed ID: 23747790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.
    Colucci WS; Elkayam U; Horton DP; Abraham WT; Bourge RC; Johnson AD; Wagoner LE; Givertz MM; Liang CS; Neibaur M; Haught WH; LeJemtel TH
    N Engl J Med; 2000 Jul; 343(4):246-53. PubMed ID: 10911006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent outpatient nesiritide infusion reduces hospital admissions in patients with advanced heart failure.
    Schwarz ER; Najam S; Akel R; Sulimanjee N; Bionat S; Rosanio S
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):232-6. PubMed ID: 17875951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.